- Topical product technology protected by patents
- Targeting $80 billion global skin care and dermatology market
- Product sales in China
Outsourcing has been the status quo in the pharmaceutical industry since long before the term gained notoriety. Large pharmaceutical and cosmeceutical companies, under pressure from rising R&D costs, have been farming out that part of their businesses for a long time now in an attempt to reduce costs. This approach also has the advantage of offloading the costs of patenting to the outsourcee. To obtain the advantages of adopting new technology, patent protection is vital to avoid copycatting. That is why the technology developed by Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has been adopted by pharmaceutical and cosmeceutical companies since 1999. The Las Vegas, Nevada–based R&D company developed Invisicare® technology, which can be used to revitalize or create new medical or skin care products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.
Invisicare is a patented polymer delivery system that improves the delivery of topically applied skin care products, thereby enhancing the efficacy of the active ingredients. The unique process extends the time the product remains active on the skin and is specifically formulated to transport active ingredients that are insoluble in water without using alcohol, silicones, waxes, or other organic solvents.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer